COYA
Coya Therapeutics, Inc.
Key Financials
Operating Income
$-22555225
↓ 30.8%
Revenue
$7.9M
↑ 123.6%
Net Income
$-21226107
↓ 42.6%
Total Assets
$50.0M
↑ 12.6%
EPS (Diluted)
$-1.27
↓ 29.6%
Shareholders' Equity
$43.0M
↑ 8.7%
Total Liabilities
$6.9M
↑ 45.1%
Cash & Equivalents
$46.8M
↑ 22.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/11/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
| 8-K/A | 8/7/2026 | View on SEC |
| SCHEDULE 13G/A | 7/27/2026 | View on SEC |
| 8-K | 6/25/2026 | View on SEC |
| ARS | 5/13/2026 | View on SEC |
| DEFA14A | 5/13/2026 | View on SEC |
| DEF 14A | 5/13/2026 | View on SEC |
| 8-K | 5/12/2026 | View on SEC |
| 424B5 | 5/12/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | COYA |
| Company Name | Coya Therapeutics, Inc. |
| CIK | 1835022 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650.739.3939 |